bioMerieux : Q3 2024 sales: at the high-end of expectations – Guidance elements confirmed
>Q3 2024: +7.8% with +11% l-f-l. (vs +9.9% in H1) - Q3 sales amounted to € 969m, +7.8% (i.e. +11% l-f-l). At 9M, sales reached € 2,871m (+7.6% and +10.3% l-f-l), impacted by a currency effect of -€ 76m, i.e. -€ 26m in Q3 (vs -€ 44m at the end of June).bioMérieux is maintaining its guidance, namely growth of between 8% and 10% at constant exchange rates. (cons.: € 3,941m +9.2%e – ODDO BHF: +8.5%e), with an expected FX impact of -€ 60m (vs € 70m previously), for an...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.